1.	Association of V	visual Impairment	with Risk for	Future Pa	rkinson's Disease
----	------------------	-------------------	---------------	-----------	-------------------

- 2
- 3 Running title: VI and Parkinson's disease
- 4
- 5 Authors
- Zhuoting Zhu, MD PhD¹ 6
- 7 Wenyi Hu, MBBS²
- 8 Huan Liao, MD³
- 9 Zachary Tan, MBBS MMed⁴
- 10 Yifan Chen, BM BCh⁵
- 11 Danli Shi, MD⁶
- 12 Xianwen Shang, PhD^{1,4}
- 13 Xueli Zhang, PhD¹
- 14 Yu Huang, MD PhD¹
- 15 Honghua Yu, MD PhD¹
- 16 Wei Wang, MD PhD⁶
- 17Mingguang He, MD PhD^{1,4,6}
- 18 Xiaohong Yang, MD PhD¹
- 19

20 Affiliations

- 21 1. Department of Ophthalmology, Guangdong Academy of Medical Sciences,
- 22 Guangdong Provincial People's Hospital, Guangzhou, China. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Zhu 2

23	2. Shanghai Jiaotong University, Shanghai, China.
24	3. Neural Regeneration Group, Institute of Reconstructive Neurobiology, University
25	of Bonn, Bonn, Germany.
26	4. Centre for Eye Research, University of Melbourne, East Melbourne, Victoria
27	Australia.
28	5. John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust
29	Oxford, UK.
30	6. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-
31	sen University, Guangzhou, China.
32	
33	Word count: Abstract: 252; Whole paper: 1980.
34	Tables: 3; Supplementary Table: 1
35	
36	Corresponding authors
37	Mingguang He, MD PhD
38	Email: mingguang.he@unimelb.edu.au
39	Xiaohong Yang, MD PhD
40	Email: syyangxh@scut.edu.cn
41	Wei Wang, MD PhD
42	Email: zoc_wangwei@yahoo.com
43	

_

44 Abstract

45	Background: Although visual dysfunction is one of the most common non-motor			
46	symptoms among patients with Parkinson's disease (PD), it is not known whether such			
47	dysfunction predates the onset of clinical PD.			
48	Objectives: To examine the association of visual impairment (VI) with the future			
49	development of PD in the UK Biobank Study.			
50	Methods: The UK Biobank Study is one of the largest prospective cohort studies of			
51	health, enrolling over 500,000 participants aged 40-69 years between 2006 and 2010			
52	across the UK. VI was defined as a habitual distance visual acuity (VA) worse than 0.3			
53	LogMAR in the better-seeing eye. Incident cases of PD were determined by self report			
54	data, hospital admission records or death records, whichever came first. Multivariable			
55	Cox proportional hazard regression models were used to investigate the association			
56	between VI and the risk of incident PD.			
57	Results: A total of 117,050 participants were free of PD at the baseline assessment.			
58	During the median observation period of 5.96 (interquantile range [IQR]: 5.77-6.23)			
59	years, PD occurred in 222 (0.19%) participants. Visually impaired participants were at			
60	a higher risk of developing PD than non-VI participants (p<0.001). Compared with the			
61	non-VI group, the adjusted hazard ratio was 2.28 (95% CI 1.29-4.04, p=0.005) in the			
62	VI group. These results were consistent in the sensitivity analysis, where incident PD			
63	cases diagnosed within one year after the baseline assessment were excluded.			

Zhu 4

_

- Conclusions: This prospective cohort study found that VI was associated with an 64
- increased risk of incident PD, suggesting that VI may represent a prodromal feature of 65
- PD. 66
- 67
- Key words: visual impairment, Parkinson's disease, ageing 68
- 69

70 Introduction

71 Parkinson's disease (PD) is the second most prevalent neurodegenerative disease and 72 affects 2-3% of the global population aged over 65¹. The total burden of disease 73 associated with PD is increasing due to ageing populations, longer disease durations 74 and environmental and social risk factors². Relatively conservative estimates predict 75 over 12 million patients will be affected by PD globally by 2050³.

76

77 In addition to motor symptoms, clinical features of PD involve many non-motor 78 symptoms exacerbating overall disability⁴. Non-motor symptoms of PD have recently 79 received increased attention as they precede the onset of motor symptoms, and may act 80 as markers of preclinical stages of PD⁵. Visual dysfunction has been reported as one of 81 the most common non-motor symptoms, and increasing evidence has demonstrated 82 higher prevalence of this non-motor symptom in PD patients compared to healthy controls⁶⁻⁹. It is yet unknown however whether visual impairment (VI), an important 83 84 indicator of visual dysfunction¹⁰, predates the onset of clinical PD. Further, 85 understanding the association between VI and future risk of PD may facilitate early 86 diagnosis and intervention of PD prior to manifestation of the full clinical syndrome.

87

88 In this context, we sought to examine the association of VI with risk of future PD 89 development using the UK Biobank, a community-based longitudinal sample.

90

91 Methods

Zhu 6

92 **Study Sample**

93 Detailed procedures of the UK Biobank study have been described elsewhere¹¹. Briefly, 94 more than 500,000 participants aged between 40-69 years were recruited at 22 95 assessment centers across the UK from 2006 to 2010. Data on lifestyle, environment and medical history were obtained using self-administered questionnaires. Physical 96 97 measurements and biological specimens including blood, urine and saliva samples were 98 also collected. Detailed follow-up of the health of participants was achieved through 99 linkage to national electronic health record datasets. Ophthalmic examinations for 100 baseline assessment were carried out from 2009 at six assessment centers. Participants 101 with available visual acuity (VA) data (n=117.252) were included in the present 102 analysis. Baseline characteristics of participants with and without VA data is shown in 103 Supplement Table 1. Relative to participants without VA data, those with available VA 104 data were more likely to be slightly older (56.8 vs. 56.4 years), of non-Caucasian 105 ethnicity, less materially deprived, non-smokers, non-drinkers, physically active, 106 diabetic, hypertensive, and less likely to use psychotropic medications. For analysis of 107 incident PD, participants diagnosed with PD prior to baseline assessment (n=174), and 108 those with self-reported PD at the baseline nurse interview (n=28) were excluded, 109 leading to a final cohort with 117,050 participants included for analysis.

110

Standard Protocol Approvals, Registrations, and Patient Consents 111

112Access to the UK Biobank data was granted after registration. The application ID was

113 62443. The UK Biobank has obtained Research Tissue Bank approval from its Research

Zhu 7

114 Ethics Committee recommended by the National Research Ethics Service (reference 115 11/NW/0382). Participants provided written informed consent.

116

117 **Assessment of Visual Acuity**

118 Detailed methods for VA testing in the UK Biobank study have been described 119 elsewhere¹². Habitual distance VA was measured using a logarithm of the minimum 120 angle of resolution (LogMAR) chart (Precision Vision, LaSalle, Illinois, USA). 121 Participants were tested at 4 meters with habitual correction if any, or at 1 meter if 122 participants were unable to read. Participants were required to read letters sequentially 123 from the top and the total number of correctly identified letters was converted to a 124 logMAR VA. Presenting VA worse than 0.3 logMAR units (equivalent to Snellen 20/40) 125 was defined as VI.

126

Ascertainment of PD 127

128 The algorithm for ascertaining PD in the UK Biobank Study could be found at in detail 129 elsewhere¹³. In brief, ascertainment of PD was based on self-reported data, diagnosis in 130 the hospital admissions data, or cause of death recorded in the national death register, 131 whichever was the earliest. Hospital admission data were retrieved from Health Episode 132Statistics records (for participants from England and Wales) and the Scottish Morbidity 133 Records (for participants from Scotland). The National Health Service (NHS) 134 Information Centre, and the NHS Central Register Scotland were used to obtain the 135 date and causes of death for participants from England and Wales, and Scotland,

Zhu 8

136	respectively. The UK Biobank study conducted a validation study on the accuracy of
137	code sources for identification of PD cases, which achieved a positive predictive value
138	(PPV) of 0.91 (95% confidence interval [CI], 0.83-0.96) when combining all sources
139	(self report, hospital admission records, and death records) ¹³ . Follow-up length was
140	calculated as the time interval between the date of baseline assessment and the censor
141	date, which is either the date of PD diagnosis, death, lost to follow-up or 1 st March 2016.
142	

143 **Covariates**

144 Consistent with previous studies¹⁴⁻¹⁷, covariates for the analysis of incident PD included age at baseline assessment (continuous), sex (male/female), ethnicity (Caucasian and 145 146 non-Caucasian), the Townsend deprivation index (continuous), smoking (current 147smoker, past smoker, and never), alcohol consumption (current and past/never drinker), 148obesity (yes/no), physical activity (above moderate/vigorous/walking recommendation, and not), history of stroke (yes/no), history of diabete mellitus (yes/no), history of 149 150hypertension (yes/no), and the use of psychotropic medications (yes/no).

151

Obesity was defined as body mass index (BMI) $\geq 30 \text{ kg/m}^2$. History of diabete mellitus 152153 was defined to include participants with either doctor-diagnosed diabetes, insulin 154 treatment or oral antidiabetic medications. History of hypertension was defined to 155include participants with either doctor-diagnosed hypertension, antihypertensive agents 156 or measured systolic pressure \geq 130 mmHg or diastolic pressure \geq 80 mmHg. The

Zhu 9

- previous use of anti-depressive, anti-migraine and axiolytic medications was defined asthe use of psychotropic medications.
- 159

160 Statistical Analysis

161	We reported normally distributed variables as means and standard deviation (SD);
162	skewed variables as median and interquartile range (IQR), and categorical variables as
163	number and percentages. Unpaired t-test and Pearson's χ^2 test were used to compare
164	continuous and categorical variables, respectively. The log-rank test was used for
165	comparison of incident PD distributions between VI and non-VI groups. The risks of
166	incident PD associated with VI were evaluated using Cox proportional hazards models
167	for estimation of hazard ratio (HR) with 95% confidence interval (CI).
168	
169	To minimize the possibility of including prevalent cases in the present analysis, a

109 To minimize the possibility of including prevalent cases in the present analysis, a 170 sensitivity analysis was performed to exclude PD cases diagnosed in the year 171 immediately following baseline assessment. Schoenfeld residuals were used to test the 172 proportional hazards assumptions for Cox models and all variables were found to be 173 valid. Two-sided p values less than 0.05 were considered statistically significant. All 174 tests were conducted using Stata version 13 (StataCorp LLC, College Station, Texas 175 USA).

176

177 Data Availability Statement

178	The UK Biobank is an open-access resource to researchers through registration of
179	proposed research. This present study was approved and registered as study 62443 with
180	the UK Biobank resource.

181

182 Results

183 A total of 117,050 participants (mean [SD] age: 56.8 [8.11] years; female: 63,695 184[54.4%]) who were free of PD at the baseline assessment were included in this present 185 analysis. Baseline characteristics of included participants are described in Table 1. A 186 total of 4,011 (3.43%) participants suffered from VI. The visually impaired participants 187 tended to be older, of non-Caucasian ethnicity, more materially deprived, current 188 smokers, non-drinkers, obese, and with a history of stroke, diabetes and hypertension. 189 There were no differences in other charateristics between the VI and non-VI group.

190

During the median follow up period of 5.96 (IQR: 5.77-6.23) years, a total of 222 cases 191 192 of PD were recorded. The incidence of PD in all participants was 0.19%, with 16 193 (7.21%) being in the VI group and 206 (92.8%) being in the non-VI group, respectively. 194 The log-rank test demonstrated a significant difference in the incidence of PD between 195 the VI and non-VI groups (p<0.001). Baseline characteristics stratified by the incidence 196 of PD are shown in Table 2. The incident PD group consisted of a greater proportion of 197 participants that were of older age, male gender, non-smokers, less physically active, 198 with a history of hypertension, and use of psychotropic medications at the baseline 199 assessment compared to the non-PD group.

200

201	The risks of developing PD for participants with and without VI based on Cox
202	proportional hazard regression models are shown in Table 3. After adjusting for age,
203	gender and ethinicity, the presence of VI was significantly associated with a higher risk
204	of developing PD (HR=2.13, 95% CI: 1.27-3.56, p=0.004). The multivariable Cox
205	proportional hazard regression model indicated that VI was associated with a 2.28-fold
206	higher risk of developing subsequent PD (95% CI: 1.29-4.04, p=0.005). Similar
207	findings were observed in the sensitivity analyses which excluded participants with PD
208	cases diagnosed in the year immediately following baseline assessment (HR=1.93, 95%
209	CI: 1.07-3.49, p=0.029, Table 3).
210	
211	Discussion

212 In this large community-based sample, we found that visually impaired individuals had 213 a 2.28 times greater risk of developing PD compared to those who did not have any VI.

214 Our findings suggest that VI may represent a prodromal feature of PD.

215

216 To the best of our knowledge, this is the first study to demonstrate that visually impaired 217 individuals are at a greater risk of developing future PD than those without. Of note, it 218 is well established that visual dysfunctions are common in PD. In a cross-sectional 219 study of the European population, PD patients had a greater than double increase in the 220 odds of having fair or poor eyesight⁹. A case-control study suggested that patients with 221 mild to moderate PD had poorer performance compared to control subjects in visual

Zhu 12

perception tasks⁶. Worsened visual function as measured by visual acuity was also
identified in PD patients in a cross-sectional study⁷.

224

225 Even though the mechanisms underlying the association of VI and incident PD were 226 unclear, several plausible explanations had been raised. Firstly, the 'bottom-up theory' postulated that impairment of the retinal dopaminergic system might explain visual 227 abnormalities in PD¹⁸. Both animal and clinical studies had suggested that 228 229 dopaminergic retinal cell loss was commonly seen in PD¹⁹⁻²². Further, aggregates of α -230 synuclein in the retina that mimiced the pathological process of PD, had been reported 231 to cause neurodegeneration of the dopaminergic cells in the retina²³. Secondly, the 'top-232 down' theory might explain visual dysfunctions observed in PD. Support for this 233 hypothesis came from evidence which demonstrated specific dysfunctions of the visual 234 cortex in PD²⁴. The depletion of neurotransmitters such as GABA and dopamine, as well as altered lipid metabolism in the visual cortex of PD patients, could account for 235 236 visual symptoms²⁵⁻²⁷. Thirdly, strong evidence in associations between ocular diseases 237 and PD might also account for the association between VI and the development of future PD²⁸. Previous studies found that ocular diseases, such as glaucoma, cataract, 238 age-related macular degeneration and diabetic retinopathy²⁹⁻³¹, shared similar 239 pathogenesis^{32, 33}, risk factors^{18, 34} and proteomics profiles³⁵ with PD. Further studies 240 241 are warranted to confirm these speculations.

242

243 Our findings have an important implication for research and public health policy. In the 244 present study, VI was identified as a potential prodromal feature of PD and might serve 245 as a novel marker for the preclinical stages of PD, potentially enabling improved early 246 diagnosis and management for those at higher risk of subsequently developing the disease. VA screening may be expanded beyond its current scope in the prevention of 247 248 sight-threatening disease.

249

250 The strengths of the present study include its large sample size, long-term follow-up 251 duration, and comprehensive adjustments for confounding factors. However, several 252 limitations should be considered. Firstly, the present analysis was solely based on 253 baseline VA. Further studies are needed to examine the impact of vision loss and/or 254other aspects of visual dysfunction on future risk of PD. Secondly, we did not have 255sufficient information to differentiate between causes of VI, thus preventing us from investigating associations between specific causes of VI and the risk of developing PD. 256 257 Thirdly, due to the nature of an observational study, the causal relationship between VI 258and incident PD cannot be confirmed. Thirdly, the UK Biobank participants were 259relatively younger and might not represent the whole population. Nevertheless, this 260 would not affect the association between VI and incident PD³⁶. Lastly, we could not 261 completely exclude the possibility of residual confounding.

262

263 Conclusions

264	In summary, we found that VI was associated with a significantly increased risk of
265	developing PD. Our findings highlighted the importance of vision screening in
266	identifying individuals at high risk of developing PD. Further studies are needed to
267	confirm our results, and the causal nature of VI and PD.

268

269 **Abbreviations and Acronyms:**

270 **PD** = Parkinson' s disease; **VI** = visual impairment; **VA** = visual acuity; **LogMAR** =

271logarithm of the minimum angle of resolution; NHS = National Health Service; IQR =

272 interquartile range; HR = hazard ratios; CI = confidence intervals; SD = standard

273 deviations; PPV = positive predictive value; BMI = body mass index

274

275 Acknowledgements: The present work was supported by the Fundamental Research 276 Funds of the State Key Laboratory of Ophthalmology, Project of Investigation on 277 Health Status of Employees in Financial Industry in Guangzhou, China (Z012014075), 278 Science and Technology Program of Guangzhou, China (202002020049). Prof. 279 Mingguang He receives support from the University of Melbourne at Research 280 Accelerator Program and the CERA Foundation. The Centre for Eye Research Australia 281 receives Operational Infrastructure Support from the Victorian State Government. The 282 sponsor or funding organization had no role in the design or conduct of this research. 283

284 Potential Conflicts of Interest: The author(s) have no potential conflicts of interest in any materials discussed in this article. 285

Zhu 15

2	8	6

287Appendix 1. Author Contributions

Name	Location	Contribution
Zhuoting Zhu, MD PhD	Guangdong Provincial People's Hospital, Guangzhou, China	Study concept and design; Drafting of the manuscript; Acquisition, analysis, or interpretation; Statistical analysis; Administrative, technical, or material support
Wenyi Hu, MBBS	Shanghai Jiaotong University, Shanghai, China	Study concept and design; Acquisition, analysis, or interpretation; Drafting of the manuscript
Huan Liao, MD	University of Bonn, Bonn, Germany	Study concept and design; Acquisition, analysis, or interpretation; Drafting of the manuscript
Zachary Tan, MBBS Mmed	University of Melbourne, Melbourne, Australia	Acquisition, analysis, or interpretation; Critical revision of the manuscript for important intellectual content
Yifan Chen, BM BCh	John Radcliffe Hospital, Oxford, UK	Acquisition, analysis, or interpretation; Critical revision of the manuscript for important intellectual content
Danli Shi, MD	Sun Yat-sen University, Guangzhou, China	Acquisition, analysis, or interpretation; Critical revision of the manuscript for important intellectual content
Xianwen Shang, PhD	University of Melbourne, Melbourne, Australia	Acquisition, analysis, or interpretation; Statistical analysis; Administrative, technical, or material support
Xueli Zhang, PhD	Guangdong Provincial People's Hospital, Guangzhou, China	Acquisition, analysis, or interpretation

perpetuity. All rights reserved. No reuse allowed without permission.

		Zhu 16
Yu Huang, MD PhD	Guangdong Provincial People's Hospital, Guangzhou, China	Acquisition, analysis, or interpretation
Honghua Yu, MD PhD	Guangdong Provincial People's Hospital, Guangzhou, China	Acquisition, analysis, or interpretation
Wei Wang, MD PhD	Sun Yat-sen University, Guangzhou, China	Acquisition, analysis, or interpretation; Critical revision of the manuscript for important intellectual content; Administrative, technical, or material support
Mingguang He, MD PhD	University of Melbourne, Melbourne, Australia	Study concept and design; Critical revision of the manuscript for important intellectual content; Obtained funding; Administrative, technical, or material support; Study supervision
Xiaohong Yang, MD PhD	Guangdong Provincial People's Hospital, Guangzhou, China	Study concept and design; Critical revision of the manuscript for important intellectual content; Obtained funding; Administrative, technical, or material support; Study supervision

288

289 **References:**

Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of
 Parkinson's disease: a review of the evidence. Eur J Epidemiol 2011;26 Suppl 1:S1-58.

292 2. Kalia LV, Lang AE. Parkinson's disease. Lancet 2015;386:896-912.

293 3. Collaborators GBDPsD. Global, regional, and national burden of Parkinson's disease, 1990294 2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol
295 2018;17:939-953.

296 4. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers 2017;3:17013.

297 5. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for
298 future Parkinson's disease. Ann Neurol 2008;63:167-173.

299 6. Uc EY, Rizzo M, Anderson SW, Qian S, Rodnitzky RL, Dawson JD. Visual dysfunction in
 300 Parkinson disease without dementia. Neurology 2005;65:1907-1913.

Polo V, Satue M, Rodrigo MJ, et al. Visual dysfunction and its correlation with retinal changes
 in patients with Parkinson's disease: an observational cross-sectional study. BMJ Open

perpetuity. All rights reserved. No reuse allowed without permission.

Zhu 17

303 2016;6:e009658.

304 8. Ming W, Palidis DJ, Spering M, McKeown MJ. Visual Contrast Sensitivity in Early-Stage
 305 Parkinson's Disease. Invest Ophthalmol Vis Sci 2016;57:5696-5704.

Hamedani AG, Willis AW. Self-reported visual dysfunction in Parkinson disease: the Survey of
 Health, Ageing and Retirement in Europe. Eur J Neurol 2020;27:484-489.

308 10. Nirmalan PK, John RK, Gothwal VK, et al. The impact of visual impairment on functional vision
309 of children in rural South India: the Kariapatti Pediatric Eye Evaluation Project. Invest Ophthalmol
310 Vis Sci 2004;45:3442-3445.

311 11. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the
 312 causes of a wide range of complex diseases of middle and old age. PLoS Med 2015;12:e1001779.

12. Chua SYL, Thomas D, Allen N, et al. Cohort profile: design and methods in the eye and visionconsortium of UK Biobank. BMJ Open 2019;9:e025077.

13. Kathryn Bush KR, Tim Wilkinson, Christian Schnier and Cathie Sudlow On behalf of UK Biobank
Outcome Adjudication Group. Definitions of Parkinson' s Disease and the Major Causes of
Parkinsonism, UK Biobank Phase 1 Outcomes Adjudication. 2018. Available at:
https://biobank.ndph.ox.ac.uk/ukb/ukb/docs/alg_outcome_pdp.pdf [Accessed on September 30,
2020].

320 14. Qiu C, Hu G, Kivipelto M, et al. Association of blood pressure and hypertension with the risk
 321 of Parkinson disease: the National FINRISK Study. Hypertension 2011;57:1094-1100.

322 15. Xu Q, Park Y, Huang X, et al. Diabetes and risk of Parkinson's disease. Diabetes Care
323 2011;34:910-915.

Kizza J, Lewington S, Mappin-Kasirer B, et al. Cardiovascular risk factors and Parkinson's
 disease in 500,000 Chinese adults. Ann Clin Transl Neurol 2019;6:624-632.

17. Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Exploring the Association Between Rosacea
 and Parkinson Disease: A Danish Nationwide Cohort Study. JAMA Neurol 2016;73:529-534.

328 18. Guo L, Normando EM, Shah PA, De Groef L, Cordeiro MF. Oculo-visual abnormalities in
 329 Parkinson's disease: Possible value as biomarkers. Mov Disord 2018;33:1390-1406.

19. Nguyen-Legros J. Functional neuroarchitecture of the retina: hypothesis on the dysfunctionof retinal dopaminergic circuitry in Parkinson's disease. Surg Radiol Anat 1988;10:137-144.

332 20. Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease.
333 Invest Ophthalmol Vis Sci 1990;31:2473-2475.

334 21. Biehlmaier O, Alam M, Schmidt WJ. A rat model of Parkinsonism shows depletion of335 dopamine in the retina. Neurochem Int 2007;50:189-195.

336 22. Ortuno-Lizaran I, Sanchez-Saez X, Lax P, et al. Dopaminergic Retinal Cell Loss and Visual
 337 Dysfunction in Parkinson Disease. Ann Neurol 2020.

338 23. Marrocco E, Indrieri A, Esposito F, et al. alpha-synuclein overexpression in the retina leads to
 339 vision impairment and degeneration of dopaminergic amacrine cells. Sci Rep 2020;10:9619.

Weil RS, Schrag AE, Warren JD, Crutch SJ, Lees AJ, Morris HR. Visual dysfunction in Parkinson's
 disease. Brain 2016;139:2827-2843.

342 25. Firbank MJ, Parikh J, Murphy N, et al. Reduced occipital GABA in Parkinson disease with visual343 hallucinations. Neurology 2018;91:e675-e685.

344 26. Armstrong RA. Visual Dysfunction in Parkinson's Disease. Int Rev Neurobiol 2017;134:921345 946.

346 27. Cheng D, Jenner AM, Shui G, et al. Lipid pathway alterations in Parkinson's disease primary

Zhu	18
2110	TO

347	visual cortex. PLoS One 2011;6:e17299.
348	28. Ekker MS, Janssen S, Seppi K, et al. Ocular and visual disorders in Parkinson's disease:
349	Common but frequently overlooked. Parkinsonism Relat Disord 2017;40:1-10.
350	29. Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet
351	2017;390:2183-2193.
352	30. Zhao J, Xu X, Ellwein LB, et al. Causes of Visual Impairment and Blindness in the 2006 and
353	2014 Nine-Province Surveys in Rural China. Am J Ophthalmol 2019;197:80-87.
354	31. Khan A, Petropoulos IN, Ponirakis G, Malik RA. Visual complications in diabetes mellitus:
355	beyond retinopathy. Diabet Med 2017;34:478-484.
356	32. Ramirez AI, de Hoz R, Salobrar-Garcia E, et al. The Role of Microglia in Retinal
357	Neurodegeneration: Alzheimer's Disease, Parkinson, and Glaucoma. Front Aging Neurosci
358	2017;9:214.
359	33. Brennan LA, Kantorow M. Mitochondrial function and redox control in the aging eye: role of
360	MsrA and other repair systems in cataract and macular degenerations. Exp Eye Res 2009;88:195-
361	203.
362	34. Zheng F, Yu M, Leung CK. Diagnostic criteria for detection of retinal nerve fibre layer thickness
363	and neuroretinal rim width abnormalities in glaucoma. Br J Ophthalmol 2020;104:270-275.
364	35. Sundstrom JM, Hernandez C, Weber SR, et al. Proteomic Analysis of Early Diabetic
365	Retinopathy Reveals Mediators of Neurodegenerative Brain Diseases. Invest Ophthalmol Vis Sci
366	2018;59:2264-2274.
367	36. Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health-Related
368	Characteristics of UK Biobank Participants With Those of the General Population. American Journal
369	of Epidemiology 2017;186:1026-1034.
370	

- 370
- 371

372 Table 1. Baseline Characteristics of the Study Participants Stratified by Visual Impairment Status

Baseline Characteristics	Total	Non-VI Group	VI Group	P value
n	117,050	113,039	4,011	-
Age, mean (SD), yrs	56.8 (8.11)	56.8 (8.12)	58.8 (7.57)	<0.001
Gender, n (%)				0.361
Female	63,695 (54.4)	61,484 (54.4)	2,211 (55.1)	
Male	53,355 (45.6)	51,555 (45.6)	1,800 (44.9)	
Ethnicity, n (%)				<0.001
White	104,128 (89.0)	100,829 (89.2)	3,299 (82.3)	
Other	12,922 (11.0)	12,210 (10.8)	712 (17.7)	

				Zhu
Townsend deprivation index, mean	-0.93 (3.01)	-0.96 (3.00)	-0.12 (3.33)	<0.001
(SD)				
Smoking status, n (%)				<0.001
Never	64,503 (55.5)	62,314 (55.5)	2,189 (55.5)	
Former	40,014 (34.4)	38,750 (34.5)	1,264 (32.0)	
Current	11,744 (10.1)	11,252 (10.0)	492 (12.5)	
Drinking status, n (%)				<0.001
Never	6,215 (5.33)	5,877 (5.22)	338 (8.54)	
Former/current	110,352 (94.7)	106,731 (94.8)	3,621 (91.5)	
Obesity, n (%)				0.001
No	87,747 (75.4)	84,859 (75.5)	2,888 (73.1)	
Yes	28,640 (24.6)	27,576 (24.5)	1,064 (26.9)	
Physical Activity				0.378
Not meeting recommendation	16,831 (17.7)	16,259 (17.7)	572 (18.3)	
Above	78,195 (82.3)	75,642 (82.3)	2,553 (81.7)	
moderate/vigorous/walking				
recommendation				
History of stroke, n (%)				<0.001
No	115,275 (98.5)	111,368 (98.5)	3,907 (97.4)	
Yes	1,775 (1.52)	1,671 (1.48)	104 (2.59)	
History of diabetes, n (%)				<0.001
No	109,222 (93.3)	105,589 (93.4)	3,633 (90.6)	
Yes	7,828 (6.69)	7,450 (6.59)	378 (9.42)	
History of hypertension, n (%)				<0.001
No	29,940 (25.6)	29,113 (25.8)	827 (20.6)	
Yes	87,110 (74.4)	83,926 (74.2)	3,184 (79.4)	
Psychotropic medications, n(%)				0.052
No	107,982 (92.3)	104,314 (92.3)	3,668 (91.5)	
Yes	9,068 (7.75)	8,725 (7.72)	343 (8.55)	

Zhu 20

373 SD = standard deviation; VI = visual impairment.

374

Zhu 21

375

376Table 2. Baseline Characteristics Stratified by Incident Parkinson Disease

Baseline Characteristics	Non-PD Group	PD Group	P value
N	116,828	222	-
Age, mean (SD), yrs	56.8 (8.11)	63.2 (5.42)	<0.001
Gender, n (%)			<0.001
Female	63,608 (54.5)	87 (39.2)	
Male	53,220 (45.5)	135 (60.8)	
Ethnicity, n (%)			0.452
White	103,927 (89.0)	201 (90.5)	
Others	12,901 (11.0)	21 (9.46)	
Townsend deprivation index, mean	-0.93 (3.01)	-1.16 (2.89)	0.258
(SD)			
Smoking status, n (%)			0.010
Never	64,389 (55.5)	114 (51.4)	
Former	39,919 (34.4)	95 (42.8)	
Current	11,731 (10.1)	13 (5.86)	
Drinking status, n (%)			0.123
Never	6,198 (5.33)	17 (7.66)	
Former/current	110,147 (94.7)	205 (92.3)	
Obesity, n (%)			0.153
No	87,591 (75.4)	156 (71.2)	
Yes	28,577 (24.6)	63 (28.8)	
Physical Activity			0.007
Not meeting recommendation	16,786 (17.7)	45 (25.4)	
Above moderate/vigorous/walking.	78,063 (82.3)	132 (74.6)	
recommendation			
History of stroke, n (%)			0.369
No	115,058 (98.5)	217 (97.8)	

			Zhu	22
Yes	1,770 (1.52)	5 (2.25)		
History of diabetes, n (%)				0.054
No	109,022 (93.3)	200 (90.1)		
Yes	7,806 (6.68)	22 (9.91)		
History of hypertension, n (%)				0.023
No	29,898 (25.6)	42 (18.9)		
Yes	86,930 (74.4)	180 (81.1)		
Psychotropic medications, n(%)			•	<0.001
No	107,798 (92.3)	184 (82.9)		
Yes	9,030 (7.73)	38 (17.1)		

377 SD = standard deviation; PD = Parkinson's disease.

378

Zhu 23

379

-					
	Age-, Gender- and Ethnicity-Adjusted		Multivariable Model ^a		
VI Status	Model				
	HR (95% CI)	P-value	HR (95% CI)	P-value	
Main analysis					
VI status					
None	1 [Reference]	-	1 [Reference]	-	
VI	2.13 (1.27-3.56)	0.004	2.28 (1.29-4.04)	0.005	
Sensitivity ana	ılysis ^b				
VI status					
None	1 [Reference]	-	1 [Reference]	-	
VI	1.79 (1.05-3.03)	0.031	1.93 (1.07-3.49)	0.029	
l VI = visual	impairment; PD = Parkinson's	disease; HR = haza	ard ratio; CI = confidence i	interval.	
^a Cox propo	^a Cox proportional hazards regression models adjusted for age, gender, race/ethnicity, Townsend				
3 deprivation	deprivation index, smoking status, drinking status, obesity, physical activity, history of stroke, history				
4 of diabetes,	of diabetes, history of hypertension, and psychotropic medications.				

380 Table 3. Cox Proportional Hazards Models for Incident Parkinson Disease by Visual Impairment Status

385 ^b Excluding incident PD diagnosed in the year immediately following baseline assessment.

386

387